Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 1st cortical or subcortical unilateral infarction (supratentorial lesion)~2. Confirmed by CT or MRI~3. Subacute stage: less than 1 week~4. Moderate to severe motor function involvement-total of FMA: 0-84~5. Age: between 18 and 80 years~6. Inpatients~Exclusion Criteria:~1. Progressive or unstable stroke~2. Pre-existing and active major neurological disease~3. Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia~4. A history of significant alcohol or drug abuse in the prior 3 years~5. Advanced liver, kidney, cardiac, or pulmonary disease~6. A terminal medical diagnosis consistent with survival \< 1 year~7. Substantial decrease in alertness at the time of randomization, defined as score of 2 on NIH Stroke Scale~8. Pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years~9. Any condition that would represent a contraindication to Cerebrolysin, including allergy to Cerebrolysin~10. Current enrolment in another therapeutic study of stroke or stroke recovery~11. Total serum bilirubin \> 4 mg/dL, alkaline phosphatase \> 250 U/L, SGOT/AST \> 150 U/L, SGPT/ALT \> 150 U/L, or creatinine \> 3.5 mg/dL; or cardiopulmonary deficits large enough to interfere with reasonable participation in physiotherapy during the trial.~12. Previous porcine brain peptide administration history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study Group 1 (Type: EXPERIMENTAL): Study Group 1: 30ml Cerebrolysin
- Study Group 2 (Type: PLACEBO_COMPARATOR): Study Group 2: Placebo (0.9% NaCl)

Based on this trial design, predict the completion outcome and termination type (if applicable).